PLAU

PLAU

PLAU Overview

Molecule Name
Urokinase plasminogen activator
Synonyms
Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs4
Highest Development StageApproved
Target Synonym
PLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC 3.4.21,EC:3.4.21.73,U-Plasminogen Activator,EC 3.4.21.73
Background
Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

PLAU Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
tPA/HisproUK (Thrombolytic Science)TS-01Phase 2 ClinicalThrombolytic Science
Ischemic Stroke
Details
Upamostat Hydrogen SulphateWX-671; LH-011; RHB-107Phase 2 ClinicalWilex AG
Coronavirus Disease 2019 (COVID-19); Metastatic breast cancer; Pancreatic Neoplasms
Details
MicrolyseTGD-001Phase 2 ClinicalUniversity Medical Centre Utrecht, Netherlands
Ischemic Stroke; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia; Thrombotic Microangiopathies
Details
Recombinant annexin A5 (Annexin Pharmaceuticals)ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5)Phase 2 ClinicalAnnexin Pharmaceuticals AB
Anemia, Sickle Cell; Cardiovascular Diseases; Diabetic Retinopathy; Neoplasms; Retinal Vein Occlusion
Details
MSB-03MSB-03Phase 1 ClinicalMatriSys Bioscience Inc
Rosacea
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Urokinase biosimilar (Sedico)ApprovedSedicoAngikinaseEgyptThromboembolism; Myocardial Infarction; Pulmonary EmbolismSedico2014-01-01
Myocardial Infarction; Pulmonary Embolism; Thromboembolism
Details
TisokinaseAK-124ApprovedAsahi Kasei Corp, Kowa Dental Health Co LtdPlasvata, HapaseJapanMyocardial Infarction; Thrombosisnull1991-01-01
Myocardial Infarction; Thrombosis
Details
Urokinase biosimilar (Bharat Serums & Vaccines)U-FRAGApprovedBharat Serums And Vaccines Ltd
Pulmonary Embolism
Details
NasaruplaseGE-0943ApprovedMitsubishi Pharma CorpTomieze, ThrombolyseJapanMyocardial Infarction; Venous ThrombosisMitsubishi Pharma Corp1992-01-01
Myocardial Infarction; Venous Thrombosis
Details